<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000774</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>1</s160></s100><s200><s210>1</s210><s211>585</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s223>Wild-type albumin from Homo sapiens</s223></s220></s200><s400> 1Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu1               5                   10                  15Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln            20                  25                  30Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu        35                  40                  45Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys    50                  55                  60Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu65                  70                  75                  80Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro                85                  90                  95Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu            100                 105                 110Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His        115                 120                 125Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg    130                 135                 140Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg145                 150                 155                 160Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala                165                 170                 175Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser            180                 185                 190Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu        195                 200                 205Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro    210                 215                 220Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys225                 230                 235                 240Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp                245                 250                 255Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser            260                 265                 270Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His        275                 280                 285Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser    290                 295                 300Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala305                 310                 315                 320Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg                325                 330                 335Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr            340                 345                 350Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu        355                 360                 365Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro    370                 375                 380Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu385                 390                 395                 400Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro                405                 410                 415Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys            420                 425                 430Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys        435                 440                 445Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His    450                 455                 460Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser465                 470                 475                 480Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr                485                 490                 495Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp            500                 505                 510Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala        515                 520                 525Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu    530                 535                 540Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys545                 550                 555                 560Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val                565                 570                 575Ala Ala Ser Gln Ala Ala Leu Gly Leu            580                 585</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000775A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000775</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17756720</doc-number><date>20201201</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>16</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>53</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>20</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>48</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>1676</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>53</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>2013</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>4808</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">SOLID PHARMACEUTICAL FORMULATIONS OF 6-(2-CHLORO-6-METHYLPYRIDIN-4-YL)-5-(4-FLUOROPHENYL)-1,2,4-TRIAZIN-3-AMINE</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>62942417</doc-number><date>20191202</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>AstraZeneca AB</orgname><address><city>S&#xf6;dert&#xe4;lje</city><country>SE</country></address></addressbook><residence><country>SE</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>HOLMGREN</last-name><first-name>Anders</first-name><address><city>S&#xf6;dert&#xe4;lje</city><country>SE</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>KYSS&#xc4;</last-name><first-name>Annika</first-name><address><city>S&#xf6;dert&#xe4;lje</city><country>SE</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>VON CORSWANT</last-name><first-name>Christian</first-name><address><city>S&#xf6;dert&#xe4;lje</city><country>SE</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>SKANTZE</last-name><first-name>Urban</first-name><address><city>S&#xf6;dert&#xe4;lje</city><country>SE</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/EP2020/084160</doc-number><date>20201201</date></document-id><us-371c12-date><date>20220601</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Solid pharmaceutical formulations including AZD4635 are described. The solid formulations can include a polymeric stabilizer (e.g., a polyvinylpyrollidone), an ionic surfactant (e.g., sodium docusate), and a non-ionic surfactant (e.g., a poloxamer).</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="115.32mm" wi="158.75mm" file="US20230000775A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="137.41mm" wi="167.89mm" file="US20230000775A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="135.38mm" wi="133.43mm" file="US20230000775A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="97.45mm" wi="158.92mm" file="US20230000775A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="168.66mm" wi="105.16mm" file="US20230000775A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="76.37mm" wi="102.70mm" file="US20230000775A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="214.88mm" wi="130.81mm" orientation="landscape" file="US20230000775A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="173.82mm" wi="136.48mm" file="US20230000775A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="181.53mm" wi="142.83mm" file="US20230000775A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><p id="p-0002" num="0001">Adenosine modulates of a number of physiological functions. Intracellularly, adenosine is involved in energy metabolism, nucleic acid metabolism, and the methionine cycle; extracellular adenosine engages in intercellular signaling. For example, extracellular adenosine is a potent immunosuppressor, preventing an overzealous immune response during inflammation and infection. Adenosine also acts on other systems, including the cardiovascular system, and the central nervous system.</p><p id="p-0003" num="0002">The action of adenosine is mediated by a family of G-protein coupled receptors. At least four subtypes of adenosine receptors have been identified: A1R, A2aR, A2bR, and A3R. The A1R and A3 subtypes inhibit the activity of the enzyme adenylate cyclase, whereas the A2a and A2b subtypes stimulate the activity of the same enzyme, thereby modulating the level of cyclic AMP in cells.</p><p id="p-0004" num="0003">In the immune system, engagement of A2a and A2b adenosine receptors is a critical regulatory mechanism that protects tissues against excessive immune reactions. In tumors, this pathway is hijacked and hinders antitumor immunity, promoting cancer progression. Furthermore, in many cases, the tumor microenvironment contains high levels of extracellular adenosine. Thus, the adenosine receptor, notably A2aR and A2bR, have been identified as targets for cancer therapies.</p><p id="p-0005" num="0004">Compound 1, 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine, has the following structure:</p><p id="p-0006" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="35.64mm" wi="38.61mm" file="US20230000775A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0007" num="0000">and is disclosed in WO 2011/095625. Compound 1 is a potent A2aR antagonist in clinical trials for treatment of cancer. Compound 1 is also known as AZD4635 or HTL-1071.</p><p id="p-0008" num="0005">Compound 1 is weakly basic, with the triazine moiety demonstrating a pKa of 1.78. Its logP value is 2.8. In aqueous media, Compound 1 is poorly soluble, with solubilities ranging from less than 5 &#x3bc;g/mL at neutral pH to 29.8 &#x3bc;g/mL at pH 1.2; in simulated fasted intestinal fluid, the solubility is 5.8 &#x3bc;g/mL.</p><p id="p-0009" num="0006">Due to its poor solubility, the bioavailability of Compound 1 is limited. It can be formulated as a powder for dosing in a mix-and-drink form. However, mix-and-drink formulations suffer from relative complexity of dosing and an unpleasant experience for the patient. Accordingly, there remains a need for a solid pharmaceutical formulation of Compound 1 which provides ease of dosing while maintaining suitable pharmacokinetic properties.</p><p id="p-0010" num="0007">In one aspect, a solid pharmaceutical formulation comprises a plurality of microcrystalline cellulose pellets each individually coated with a composition comprising: 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; a polymeric stabilizer; an ionic surfactant; and a non-ionic surfactant.</p><p id="p-0011" num="0008">The polymeric stabilizer can include polyvinylpyrollidone.</p><p id="p-0012" num="0009">The ionic surfactant can include sodium docusate.</p><p id="p-0013" num="0010">The non-ionic surfactant can include a poloxamer or a PEGylated phospholipid.</p><p id="p-0014" num="0011">In some embodiments, the polymeric stabilizer can include polyvinylpyrollidone, the ionic surfactant can include sodium docusate, and the non-ionic surfactant can include a poloxamer or a PEGylated phospholipid.</p><p id="p-0015" num="0012">The polymeric stabilizer can be polyvinylpyrollidone K-30.</p><p id="p-0016" num="0013">The ionic surfactant can be sodium docusate.</p><p id="p-0017" num="0014">The non-ionic surfactant can be poloxamer 407.</p><p id="p-0018" num="0015">In some embodiments, the polymeric stabilizer can be polyvinylpyrollidone K-30, the ionic surfactant can be sodium docusate, and the non-ionic surfactant can be poloxamer 407.</p><p id="p-0019" num="0016">The composition can further comprise trehalose.</p><p id="p-0020" num="0017">The composition can comprise, on a w/w % basis: from 20 to 75% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine.</p><p id="p-0021" num="0018">The composition can comprise, on a w/w % basis: from 1 to 20% of polyvinylpyrollidone K-30.</p><p id="p-0022" num="0019">The composition can comprise, on a w/w % basis: from 0.01 to 1.00% of sodium docusate.</p><p id="p-0023" num="0020">The composition can comprise, on a w/w % basis: from 20 to 60% of poloxamer 407.</p><p id="p-0024" num="0021">In some embodiments, the composition can comprise, on a w/w % basis: from 20 to 75% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; from 1 to 20% of polyvinylpyrollidone K-30; from 0.01 to 1.00% of sodium docusate; and from 20 to 60% of poloxamer 407.</p><p id="p-0025" num="0022">The formulation can include, on a w/w % basis: from 10 to 50% of microcrystalline cellulose.</p><p id="p-0026" num="0023">The formulation can include, on a w/w % basis: from 20 to 50% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine.</p><p id="p-0027" num="0024">The formulation can include, on a w/w % basis: from 0.1 to 10% of polyvinylpyrollidone K-30.</p><p id="p-0028" num="0025">The formulation can include, on a w/w % basis: from 0.01 to 1.00% of sodium docusate.</p><p id="p-0029" num="0026">The formulation can include, on a w/w % basis: from 10 to 40% of poloxamer 407.</p><p id="p-0030" num="0027">In some embodiments, the formulation includes, on a w/w % basis: from 10 to 50% of microcrystalline cellulose; from 20 to 50% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; from 0.1 to 10% of polyvinylpyrollidone K-30; from 0.01 to 1.00% of sodium docusate; and from 10 to 40% of poloxamer 407.</p><p id="p-0031" num="0028">The formulation can further comprise a lubricant. The lubricant can include sodium stearyl fumarate.</p><p id="p-0032" num="0029">The formulation can include, on a w/w % basis: from 25 to 40% of microcrystalline cellulose.</p><p id="p-0033" num="0030">The formulation can include, on a w/w % basis: from 25 to 45% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine.</p><p id="p-0034" num="0031">The formulation can include, on a w/w % basis: from 3 to 7% of PVP K30.</p><p id="p-0035" num="0032">The formulation can include, on a w/w % basis: from 0.05 to 0.50% of sodium docusate.</p><p id="p-0036" num="0033">The formulation can include, on a w/w % basis: from 15 to 35% of poloxamer 407.</p><p id="p-0037" num="0034">The formulation can include, on a w/w % basis: from 0.01 to 0.5% of sodium stearyl fumarate.</p><p id="p-0038" num="0035">In some embodiments, the formulation can include, on a w/w % basis: from 25 to 40% of microcrystalline cellulose; from 25 to 45% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; from 3 to 7% of PVP K30; from 0.05 to 0.50% of sodium docusate; from 15 to 35% of poloxamer 407; and from 0.01 to 0.5% of sodium stearyl fumarate.</p><p id="p-0039" num="0036">The formulation can include, on a w/w % basis: from 30 to 35% of microcrystalline cellulose.</p><p id="p-0040" num="0037">The formulation can include, on a w/w % basis: from 33 to 39% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine.</p><p id="p-0041" num="0038">The formulation can include, on a w/w % basis: from 4.2 to 5.2% of PVP K30.</p><p id="p-0042" num="0039">The formulation can include, on a w/w % basis: from 0.2 to 0.3% of sodium docusate.</p><p id="p-0043" num="0040">The formulation can include, on a w/w % basis: from 22 to 28% of poloxamer 407.</p><p id="p-0044" num="0041">The formulation can include, on a w/w % basis: from 0.15 to 0.25% of sodium stearyl fumarate.</p><p id="p-0045" num="0042">In some embodiments, the formulation can include, on a w/w % basis: from 30 to 35% of microcrystalline cellulose; from 33 to 39% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; from 4.2 to 5.2% of PVP K30; from 0.2 to 0.3% of sodium docusate; from 22 to 28% of poloxamer 407; and from 0.15 to 0.25% of sodium stearyl fumarate.</p><p id="p-0046" num="0043">In another aspect, a solid pharmaceutical formulation comprises a plurality of microcrystalline cellulose pellets each individually coated with a composition, wherein the composition consists essentially of, on a w/w % basis: 54.44% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; 7.08% of PVP K30; 0.38% of sodium docusate; and 38.1% of poloxamer 407.</p><p id="p-0047" num="0044">In another aspect, a solid pharmaceutical formulation comprises 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine wherein an oral dose of 50 mg 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine to a human subject provides an AUC<sub>0-48 </sub>of 1850 ng&#xb7;h/mL&#xb1;30%. This solid pharmaceutical formulation can comprise a plurality of microcrystalline cellulose pellets each individually coated with a composition comprising: 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; a polymeric stabilizer; an ionic surfactant; and a non-ionic surfactant. The polymeric stabilizer can include polyvinylpyrollidone. The ionic surfactant can include sodium docusate. The non-ionic surfactant can include a poloxamer or a PEGylated phospholipid. In some embodiments, the polymeric stabilizer can include polyvinylpyrollidone, the ionic surfactant can include sodium docusate, and the non-ionic surfactant can include a poloxamer or a PEGylated phospholipid. In some embodiments, the formulation includes, on a w/w % basis: from 10 to 50% of microcrystalline cellulose; from 20 to 50% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; from 0.1 to 10% of polyvinylpyrollidone K-30; from 0.01 to 1.00% of sodium docusate; and from 10 to 40% of poloxamer 407.</p><p id="p-0048" num="0045">In another aspect, a solid pharmaceutical formulation comprises 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine wherein an oral dose of 50 mg 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine to a human subject provides a C<sub>max </sub>of 352 ng/mL&#xb1;30%. This solid pharmaceutical formulation can comprise a plurality of microcrystalline cellulose pellets each individually coated with a composition comprising: 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; a polymeric stabilizer; an ionic surfactant; and a non-ionic surfactant. The polymeric stabilizer can include polyvinylpyrollidone. The ionic surfactant can include sodium docusate. The non-ionic surfactant can include a poloxamer or a PEGylated phospholipid. In some embodiments, the polymeric stabilizer can include polyvinylpyrollidone, the ionic surfactant can include sodium docusate, and the non-ionic surfactant can include a poloxamer or a PEGylated phospholipid. In some embodiments, the formulation includes, on a w/w % basis: from 10 to 50% of microcrystalline cellulose; from 20 to 50% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; from 0.1 to 10% of polyvinylpyrollidone K-30; from 0.01 to 1.00% of sodium docusate; and from 10 to 40% of poloxamer 407.</p><p id="p-0049" num="0046">In another aspect, a solid pharmaceutical formulation comprises 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine wherein an oral dose of 50 mg 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine to a human subject provides an AUC<sub>0-48 </sub>of 1850 ng&#xb7;h/mL&#xb1;30% and a C<sub>max </sub>of 352 ng/mL&#xb1;30%. This solid pharmaceutical formulation can comprise a plurality of microcrystalline cellulose pellets each individually coated with a composition comprising: 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; a polymeric stabilizer; an ionic surfactant; and a non-ionic surfactant. The polymeric stabilizer can include polyvinylpyrollidone. The ionic surfactant can include sodium docusate. The non-ionic surfactant can include a poloxamer or a PEGylated phospholipid. In some embodiments, the polymeric stabilizer can include polyvinylpyrollidone, the ionic surfactant can include sodium docusate, and the non-ionic surfactant can include a poloxamer or a PEGylated phospholipid. In some embodiments, the formulation includes, on a w/w % basis: from 10 to 50% of microcrystalline cellulose; from 20 to 50% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; from 0.1 to 10% of polyvinylpyrollidone K-30; from 0.01 to 1.00% of sodium docusate; and from 10 to 40% of poloxamer 407.</p><p id="p-0050" num="0047">In another aspect, a solid unit dosage form of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine includes 1 to 200 mg of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine in a gelatin capsule. The solid unit dosage form of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine can include 50, 75, or 100 mg of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine.</p><p id="p-0051" num="0048">Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><p id="p-0052" num="0049"><figref idref="DRAWINGS">FIG. <b>1</b></figref> is a graph showing particle size distributions for milled (right bars) and re-dispersed (left bars) API.</p><p id="p-0053" num="0050"><figref idref="DRAWINGS">FIG. <b>2</b></figref> is a graph showing particle size distributions for two different nanosuspension formulations.</p><p id="p-0054" num="0051"><figref idref="DRAWINGS">FIG. <b>3</b></figref> is a graph showing % release of API from four different tablet formulations.</p><p id="p-0055" num="0052"><figref idref="DRAWINGS">FIGS. <b>4</b>A-<b>4</b>C</figref> are graphs showing time courses of API plasma concentration in dogs of Formulation 1 (<figref idref="DRAWINGS">FIG. <b>4</b>A</figref>), Formulation 3 (<figref idref="DRAWINGS">FIG. <b>4</b><i>b</i></figref>), and Formulation 4C (<figref idref="DRAWINGS">FIG. <b>4</b>C</figref>).</p><p id="p-0056" num="0053"><figref idref="DRAWINGS">FIG. <b>5</b></figref> is a process flow chart for preparation of capsules, e.g., of Formulation 8a.</p><p id="p-0057" num="0054"><figref idref="DRAWINGS">FIGS. <b>6</b>A-<b>6</b>D</figref> are graphs showing time courses of API plasma concentration in dogs of Formulation 1 (<figref idref="DRAWINGS">FIG. <b>6</b>A</figref>), Formulation 8b (<figref idref="DRAWINGS">FIG. <b>6</b>B</figref>), Formulation 8a (<figref idref="DRAWINGS">FIG. <b>6</b>C</figref>), and Formulation 7b (<figref idref="DRAWINGS">FIG. <b>6</b>D</figref>).</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><p id="p-0058" num="0055">Described herein are solid pharmaceutical formulations of Compound 1. The solid pharmaceutical formulations are suitable for oral dosing and provide suitable qualities, e.g., dissolution and absorption so as to afford desired pharmacokinetic behavior in subjects.</p><p id="p-0059" num="0056">The inventors investigated multiple strategies to make an effective solid formulation, including:<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0057">Conventional immediate release tablets. Overall drug exposure was limited by low solubility of Compound 1; not considered feasible.</li>        <li id="ul0002-0002" num="0058">Salt form/co-crystal: Salt screen only showed formation of salt with strong acids which then rapidly dissociated on contact with water. Screen of co-crystal former molecules was unsuccessful in identifying a suitable co-crystal form.</li>        <li id="ul0002-0003" num="0059">Lipid formulation: Compound 1 is a neutral molecule, and not lipophilic. Lipidic screen did not show significant solubility in suitable excipients for making a true lipidic formulation.</li>        <li id="ul0002-0004" num="0060">Mesoporous silica formulation: Such formulations require adequate solubility of API in suitable solvent and amorphous stability. Solubility of Compound 1 inadequate.</li>        <li id="ul0002-0005" num="0061">Spray-dried amorphous solid dispersion: Compound 1 has limited solubility in solvents suitable for spray drying.</li>        <li id="ul0002-0006" num="0062">Hot melt extruded amorphous solid dispersion: Screening demonstrated stability of such solid dispersions at low drug loading levels. Microdissolution and dissolution showed increased and sustained release of Compound 1 compared to crystalline Compound 1.</li>        <li id="ul0002-0007" num="0063">Crystalline nanoparticles: Nanocrystalline Compound 1 coated on an insoluble core. Demonstrated enhanced dissolution rate by increasing surface area.</li>    </ul>    </li></ul></p><p id="p-0060" num="0064">Hot melt extrusion amorphous solid dispersion formulations and crystalline nanoparticle formulations were further developed as described below.</p><heading id="h-0001" level="1">EXAMPLE 1</heading><heading id="h-0002" level="1">Phase 1a Formulation</heading><p id="p-0061" num="0065">For Phase la studies, a mix-and-drink formulation (Formulation 1) was developed. Compound 1 was wet bead milled to achieve sub-micron particle size. A range of polymeric, non-ionic and ionic surfactant/nanosuspension stabilising systems were evaluated. Spray drying was chosen as the method to transform the nanosuspension into a solid product. Sucrose was added to the nanosuspension formulation prior to spray drying as a matrix former, to prevent agglomeration of the API nanoparticles and maintain the rapid dissolution characteristics of the particles on reconstitution of the suspension. A 1.0% w/w suspension was developed for use in the spray drying process to yield a 5.5% w/w Compound 1 powder for oral suspension. The dried powder was reconstituted in water containing 2 mg/mL simethicone before dosing.</p><p id="p-0062" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 1 (nanosuspension)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="77pt" align="left"/><tbody valign="top"><row><entry/><entry>Component</entry><entry>% w/w</entry><entry>Function</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="63pt" align="char" char="."/><colspec colname="3" colwidth="77pt" align="left"/><tbody valign="top"><row><entry/><entry>Compound 1</entry><entry>5.5</entry><entry>Drug substance</entry></row><row><entry/><entry>HPMC</entry><entry>27.6</entry><entry>Polymeric stabilizer</entry></row><row><entry/><entry>sucrose</entry><entry>38.7</entry><entry>Matrix former</entry></row><row><entry/><entry>docusate sodium</entry><entry>0.6</entry><entry>Surfactant</entry></row><row><entry/><entry>Poloxamer 188</entry><entry>27.6</entry><entry>Surfactant</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0003" level="1">EXAMPLE 2</heading><heading id="h-0004" level="1">Formulation 2 Nanosuspension</heading><heading id="h-0005" level="1">Example 2A</heading><heading id="h-0006" level="1">Feasibility Study</heading><p id="p-0063" num="0066">A slurry was made by first adding sodium docusate then dissolving PVP K30, then adding Compound 1, followed by milling in a planetary ceramic vessel mill into a nano-sized suspension. See <figref idref="DRAWINGS">FIG. <b>1</b></figref>. This experiment showed that it was possible to mill Compound 1 to nanosize particles with this formulation.</p><p id="p-0064" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 2 (nanosuspension)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="77pt" align="left"/><colspec colname="4" colwidth="35pt" align="left"/><tbody valign="top"><row><entry>Milled suspension</entry><entry/><entry>Pellet coating</entry><entry/></row><row><entry>composition</entry><entry/><entry>composition</entry><entry/></row><row><entry>(dry based)</entry><entry>% w/w</entry><entry>(dry based)</entry><entry>% w/w</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="35pt" align="char" char="."/><colspec colname="3" colwidth="77pt" align="left"/><colspec colname="4" colwidth="35pt" align="char" char="."/><tbody valign="top"><row><entry>Compound 1</entry><entry>87.2</entry><entry>Compound 1</entry><entry>46.6</entry></row><row><entry>PVP K30</entry><entry>12.2</entry><entry>PVP K30</entry><entry>6.5</entry></row><row><entry>Docusate Sodium</entry><entry>0.6</entry><entry>Docusate Sodium</entry><entry>0.3</entry></row><row><entry/><entry/><entry>Solid matrix former</entry><entry>46.6</entry></row><row><entry/><entry/><entry>(Trehalose or PVP K17)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0065" num="0067">It also proved it was possible (but with process difficulties) to spraycoat the suspension on MCC cores using trehalose as matrix former. Redispersion of spraycoated pellets showed the same particle size distribution as post-milled suspension.</p><heading id="h-0007" level="1">Example 2B</heading><heading id="h-0008" level="1">Particle Size Distribution</heading><p id="p-0066" num="0068">Particle size distributions for nanosuspensions of Formulation 3 and Formulation 1 were compared. See <figref idref="DRAWINGS">FIG. <b>2</b></figref>. Formulation 3 had a smaller average size and was more monodisperse than Formulation 1.</p><p id="p-0067" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 3 (nanosuspension)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="77pt" align="left"/><tbody valign="top"><row><entry/><entry>Component</entry><entry>% w/w</entry><entry>Function</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="63pt" align="char" char="."/><colspec colname="3" colwidth="77pt" align="left"/><tbody valign="top"><row><entry/><entry>Compound 1</entry><entry>78.8</entry><entry>Drug substance</entry></row><row><entry/><entry>PVP</entry><entry>5.1</entry><entry>Polymeric stabilizer</entry></row><row><entry/><entry>Docusate sodium</entry><entry>0.3</entry><entry>surfactant</entry></row><row><entry/><entry>DSPE-PEG2000</entry><entry>15.8</entry><entry>surfactant</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0068" num="0069">Formulation 3 was found to dissolve rapidly (&#x3e;90% in 10 min) and completely (98%) under USP2 conditions, pH 1.2, 2% SDS, 50 rpm, using 100 mg of Compound 1.</p><heading id="h-0009" level="1">Example 2C</heading><heading id="h-0010" level="1">Extrudate</heading><p id="p-0069" num="0070">A series of extrudate tablet formulations according to Tables 4A-4D were prepared. Dissolution profiles in Fasted state simulated intestinal fluid (FaSSIF V2) of corresponding Tablets 1-4 are shown in <figref idref="DRAWINGS">FIG. <b>3</b></figref>.</p><p id="p-0070" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4A</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 4A (Tablet 1)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="98pt" align="left"/><tbody valign="top"><row><entry>Component</entry><entry>% w/w</entry><entry>Function</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="49pt" align="char" char="."/><colspec colname="3" colwidth="98pt" align="left"/><tbody valign="top"><row><entry>Extrudate (15:85 </entry><entry>50</entry><entry>Drug substance:polymer carrier</entry></row><row><entry>Compound 1:Soluplus)</entry><entry/><entry/></row><row><entry>Lactose</entry><entry>38</entry><entry>Soluble filler</entry></row><row><entry>Crospovidone</entry><entry>10</entry><entry>Disintegrant</entry></row><row><entry>CSD</entry><entry>1</entry><entry>Glidant</entry></row><row><entry>SSF</entry><entry>1</entry><entry>lubricant</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0071" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4B</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 4B (Tablet 2)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="98pt" align="left"/><tbody valign="top"><row><entry>Component</entry><entry>% w/w</entry><entry>Function</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="49pt" align="char" char="."/><colspec colname="3" colwidth="98pt" align="left"/><tbody valign="top"><row><entry>Extrudate (15:85 </entry><entry>50</entry><entry>Drug substance:polymer carrier</entry></row><row><entry>Compound 1:Soluplus)</entry><entry/><entry/></row><row><entry>Mannitol</entry><entry>30.4</entry><entry>Soluble filler</entry></row><row><entry>DCPA</entry><entry>7.6</entry><entry>Soluble filler</entry></row><row><entry>Crospovidone</entry><entry>10</entry><entry>Disintegrant</entry></row><row><entry>CSD</entry><entry>1</entry><entry>Glidant</entry></row><row><entry>SSF</entry><entry>1</entry><entry>lubricant</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0072" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4C</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 4C (Tablet 3)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="98pt" align="left"/><tbody valign="top"><row><entry>Component</entry><entry>% w/w</entry><entry>Function</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="49pt" align="char" char="."/><colspec colname="3" colwidth="98pt" align="left"/><tbody valign="top"><row><entry>Extrudate (15:85 </entry><entry>50</entry><entry>Drug substance:polymer carrier</entry></row><row><entry>Compound 1:Soluplus)</entry><entry/><entry/></row><row><entry>Mannitol</entry><entry>19</entry><entry>Soluble filler</entry></row><row><entry>MCC</entry><entry>19</entry><entry>Insoluble filler</entry></row><row><entry>Crospovidone</entry><entry>10</entry><entry>Disintegrant</entry></row><row><entry>CSD</entry><entry>1</entry><entry>Glidant</entry></row><row><entry>SSF</entry><entry>1</entry><entry>lubricant</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry namest="1" nameend="3" align="left" id="FOO-00001">Extrudate particle size (&#x3bc;m): D<sub>0.5 </sub>= 47.6; D<sub>0.9 </sub>= 194</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00002">Tablet disintegration time &#x3c; 1 min</entry></row></tbody></tgroup></table></tables></p><p id="p-0073" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4D</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 4D (Tablet 4)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="98pt" align="left"/><tbody valign="top"><row><entry>Component</entry><entry>% w/w</entry><entry>Function</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="49pt" align="char" char="."/><colspec colname="3" colwidth="98pt" align="left"/><tbody valign="top"><row><entry>Extrudate (15:85</entry><entry>70</entry><entry>Drug substance:polymer carrier</entry></row><row><entry>Compound 1:Soluplus)</entry><entry/><entry/></row><row><entry>Mannitol</entry><entry>14.4</entry><entry>Soluble filler</entry></row><row><entry>DCPA</entry><entry>3.6</entry><entry>Soluble filler</entry></row><row><entry>Crospovidone</entry><entry>10</entry><entry>Disintegrant</entry></row><row><entry>CSD</entry><entry>1</entry><entry>Glidant</entry></row><row><entry>SSF</entry><entry>1</entry><entry>lubricant</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0074" num="0071">Tablets 1-4 achieved less than 70% release within 30 min, and a maximum of &#x2dc;80% release within 90 min. See <figref idref="DRAWINGS">FIG. <b>3</b></figref>.</p><heading id="h-0011" level="1">EXAMPLE 3</heading><heading id="h-0012" level="1">Dog Study 1</heading><p id="p-0075" num="0072">Pharmacokinetic parameters of Formulation 1 (<figref idref="DRAWINGS">FIG. <b>4</b>A</figref>) and Formulation 3 (<figref idref="DRAWINGS">FIG. <b>4</b>B</figref>) and Formulation 4C (<figref idref="DRAWINGS">FIG. <b>4</b>C</figref>) were compared in dogs. Formulation 4C showed poor and inconsistent pharmacokinetics. Results for Formulations 1 and 3 are summarized in Table 4, expressed as relative ratios for Formulation 3:Formulation 1.</p><p id="p-0076" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Dog study 1</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="77pt" align="center"/><tbody valign="top"><row><entry/><entry>Animal</entry><entry>Rel Cmax*</entry><entry>Rel AUC 0-t*</entry><entry>Rel AUC 0-inf*</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>1</entry><entry>0.74</entry><entry>0.61</entry><entry>1.04</entry></row><row><entry/><entry>2</entry><entry>0.52</entry><entry>0.78</entry><entry>0.81</entry></row><row><entry/><entry>3</entry><entry>0.54</entry><entry>0.91</entry><entry>0.98</entry></row><row><entry/><entry>4</entry><entry>0.44</entry><entry>0.54</entry><entry>0.68</entry></row><row><entry/><entry>Average</entry><entry/><entry>0.71</entry><entry>0.89</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0077" num="0073">Formulation 3 had lower exposure compared to Formulation 1. Possible causes were surmised to be:<ul id="ul0003" list-style="none">    <li id="ul0003-0001" num="0000">    <ul id="ul0004" list-style="none">        <li id="ul0004-0001" num="0074">Aggregation of Formulation 3 in stomach and small intestine leading to decreased dissolution rate which limits absorption.</li>        <li id="ul0004-0002" num="0075">The excipients of Formulation 1 provided additional solubilisation of Compound 1 which increased transport to cell wall (Ullevi effect).</li>        <li id="ul0004-0003" num="0076">The excipients of Formulation 1 enhanced absorption of Compound 1.</li>    </ul>    </li></ul></p><heading id="h-0013" level="1">EXAMPLE 4</heading><heading id="h-0014" level="1">Process Flow for Pellets</heading><p id="p-0078" num="0077"><figref idref="DRAWINGS">FIG. <b>5</b></figref> illustrates the process flow for manufacture of coated microcrystalline pellets, and, where applicable, subsequent loading of the pellets into capsules. Initially, the API (Compound 1) can be dry milled in an optional PIN milling process. The milled Compound 1 was then mixed with water, ionic surfactant, and polymeric stabilizer to form a slurry. The slurry was wet milled, yielding a nanosuspension. The nanosuspension was then mixed with additional water and non-ionic surfactant. The resulting suspension was then coated on microcrystalline cellulose in a fluid bed coating process. The pellets can then be used as-is, or where applicable, further processed for loading in capsules. For capsule loading, pellets were blended with lubricant (e.g., sodium stearyl fumarate or magnesium stearate) prior to capsule filling.</p><heading id="h-0015" level="1">EXAMPLE 5</heading><heading id="h-0016" level="1">Formulation 5 Pellets</heading><p id="p-0079" num="0078">A pellet formulation (Formulation 5) was developed based on Formulation 3, changing DSPE-PEG2000 for Poloxamer 407, and adjusting ratios of components. Formulation 5 was then formed into pellets by coating on microcrystalline cellulose.</p><p id="p-0080" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 5</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 5</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="42pt" align="left"/><colspec colname="1" colwidth="112pt" align="left"/><colspec colname="2" colwidth="63pt" align="left"/><tbody valign="top"><row><entry/><entry>Pellet coating suspension</entry><entry/></row><row><entry/><entry>composition (dry based)</entry><entry>% w/w</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="42pt" align="left"/><colspec colname="1" colwidth="112pt" align="left"/><colspec colname="2" colwidth="63pt" align="char" char="."/><tbody valign="top"><row><entry/><entry>Compound 1</entry><entry>31.9</entry></row><row><entry/><entry>PVP K30</entry><entry>4.1</entry></row><row><entry/><entry>Docusate Sodium</entry><entry>0.2</entry></row><row><entry/><entry>Poloxamer 407</entry><entry>31.9</entry></row><row><entry/><entry>Trehalose</entry><entry>31.9</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0017" level="1">EXAMPLE 6</heading><heading id="h-0018" level="1">Microcrystalline Cellulose Nanopellet</heading><p id="p-0081" num="0079">Following the method of Example 4, a coating suspension was prepared (Formulation 6), and coated on to microcrystalline cellulose (Vivapur 350, approx. particle size 450 &#x3bc;m) in a fluid-bed coating process, either as-is (Formulation 7a) or with trehalose (Formulation 7b). Suitable particle sizes for milled API are particles D<sub>90</sub>&#x3c;5 &#x3bc;m and D<sub>50</sub>&#x3c;2 &#x3bc;m, and smaller.</p><p id="p-0082" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 6</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 6</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="77pt" align="left"/><tbody valign="top"><row><entry/><entry>Component</entry><entry>% w/w</entry><entry>Function</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="63pt" align="char" char="."/><colspec colname="3" colwidth="77pt" align="left"/><tbody valign="top"><row><entry/><entry>Compound 1</entry><entry>54.44</entry><entry>Drug substance</entry></row><row><entry/><entry>PVP K30</entry><entry>7.08</entry><entry>Polymeric stabilizer</entry></row><row><entry/><entry>Sodium Docusate</entry><entry>0.38</entry><entry>Ionic surfactant</entry></row><row><entry/><entry>Poloxamer 407</entry><entry>38.1</entry><entry>Non-ionic surfactant</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0083" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 7a and Formulation 7b</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>Component</entry><entry>7a, % w/w</entry><entry>7b, % w/w</entry><entry>Function</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="35pt" align="char" char="."/><colspec colname="3" colwidth="49pt" align="char" char="."/><colspec colname="4" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>API, %</entry><entry>36.29</entry><entry>25.28</entry><entry>Drug substance</entry></row><row><entry>PVP K30, %</entry><entry>4.72</entry><entry>3.29</entry><entry>Polymeric stabilizer</entry></row><row><entry>Sodium Docusate</entry><entry>0.25</entry><entry>0.177</entry><entry>Ionic surfactant</entry></row><row><entry>Poloxamer 407</entry><entry>25.40</entry><entry>25.28</entry><entry>Non-ionic surfactant</entry></row><row><entry>Trehalose</entry><entry>0.00</entry><entry>12.641</entry><entry>Matrix former</entry></row><row><entry>mcc pellets</entry><entry>33.33</entry><entry>33.33</entry><entry>Pellet core</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0084" num="0080">The pellets of Formulations 7a and 7b were blended with lubricant (sodium stearyl fumarate) according to Formulations 8a and 8b and loaded encapsulated in a gelatin capsule, with a dose of 50 mg of Compound 1 per capsule.</p><p id="p-0085" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 8</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Formulation 8a and Formulation 8b</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>Component</entry><entry>8a, % w/w</entry><entry>8b, % w/w</entry><entry>Function</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="35pt" align="char" char="."/><colspec colname="3" colwidth="49pt" align="char" char="."/><colspec colname="4" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>Compound 1</entry><entry>36.220</entry><entry>25.232</entry><entry>Drug substance</entry></row><row><entry>PVP K30</entry><entry>4.709</entry><entry>3.28</entry><entry>Polymeric stabilizer</entry></row><row><entry>sodium docusate</entry><entry>0.254</entry><entry>0.177</entry><entry>Ionic surfactant</entry></row><row><entry>Poloxamer 407</entry><entry>25.354</entry><entry>25.232</entry><entry>Non-ionic surfactant</entry></row><row><entry>trehalose</entry><entry>0.000</entry><entry>12.616</entry><entry>Matrix former</entry></row><row><entry>mcc pellets</entry><entry>33.263</entry><entry>33.263</entry><entry>Pellet core</entry></row><row><entry>sodium stearyl </entry><entry>0.200</entry><entry>0.200</entry><entry>Lubricant</entry></row><row><entry>fumarate</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0019" level="1">Example 7</heading><heading id="h-0020" level="1">Dog Study 2</heading><p id="p-0086" num="0081">The pharmacokinetic properties of Formulation 1, the capsules of Formulation 8a, the capsules of Formulation 8b, and Formulation 7b as a nanosuspension were measured in dogs (oral dosing, dogs pretreated with omeprazole). Results are summarized in Table 9 (AUC, expressed as F<sub>rel </sub>% compared to Formulation 1) and Table 10 (C<sub>max</sub>, expressed as % compared to Formulation 1). Time courses are shown in <figref idref="DRAWINGS">FIG. <b>6</b>A</figref> (Formulation 1), <figref idref="DRAWINGS">FIG. <b>6</b>B</figref> (Formulation 8b), <figref idref="DRAWINGS">FIG. <b>6</b>C</figref> (Formulation 8a), and <figref idref="DRAWINGS">FIG. <b>6</b>D</figref> (Formulation 7b).</p><p id="p-0087" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 9</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Dog Study 2, AUC F<sub>rel</sub>, %</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="14pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Dog 1</entry><entry>Dog 2</entry><entry>Dog 3</entry><entry>Dog 4</entry><entry>mean</entry></row><row><entry/><entry namest="offset" nameend="6" align="center" rowsep="1"/></row><row><entry/><entry>8b</entry><entry>0.76</entry><entry>0.78</entry><entry>0.78</entry><entry>0.77</entry><entry>0.77</entry></row><row><entry/><entry>8a</entry><entry>0.91</entry><entry>0.98</entry><entry>0.76</entry><entry>0.91</entry><entry>0.89</entry></row><row><entry/><entry>7b</entry><entry>1.22</entry><entry>1.32</entry><entry>0.93</entry><entry>1.14</entry><entry>1.15</entry></row><row><entry/><entry namest="offset" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0088" num="0000"><tables id="TABLE-US-00014" num="00014"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 10</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Dog Study 2, C<sub>max</sub>, %</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="14pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Dog 1</entry><entry>Dog 2</entry><entry>Dog 3</entry><entry>Dog 4</entry><entry>mean</entry></row><row><entry/><entry namest="offset" nameend="6" align="center" rowsep="1"/></row><row><entry/><entry>8b</entry><entry>0.82</entry><entry>0.56</entry><entry>0.85</entry><entry>0.82</entry><entry>0.76</entry></row><row><entry/><entry>8a</entry><entry>1.02</entry><entry>0.77</entry><entry>0.51</entry><entry>0.89</entry><entry>0.80</entry></row><row><entry/><entry>7b</entry><entry>1.43</entry><entry>1.38</entry><entry>0.87</entry><entry>1.13</entry><entry>1.21</entry></row><row><entry/><entry namest="offset" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0089" num="0082">Both capsule formulations 8a and 8b had relative AUC&#x3e;0.7 compared to Formulation 1, and had relative C<sub>max</sub>&#x3e;0.7 compared to Formulation 1. Formulation 8a showed higher AUC than 8b. In addition, Formulation 8b exhibited degradation when upon storage at temperatures of 50&#xb0; C. The pellets of Formulation 8a re-dispersed to smaller particles than those of Formulation 8b. Formulation 8a was progressed to a human relative bioavailability study.</p><heading id="h-0021" level="1">Example 8</heading><heading id="h-0022" level="1">Human Relative Bioavailability Study</heading><p id="p-0090" num="0083">Following administration of AZD4635 nanosuspension (Formulation 1) to human subjects in the fasted state, plasma AZD4635 concentrations were quantifiable from the first sampling time point of 0.25 hour post-dose in all subjects. Thereafter, concentrations remained quantifiable until 24 to 48 hours post-dose. Maximum plasma concentrations occurred between 0.5 hour and 2 hours post-dose (median t<sub>max </sub>of 1 hour). Geometric mean (CV %) values for C<sub>max</sub>, AUC<sub>0-t </sub>and AUC were 276 ng/mL (16.7), 1670 ng&#xb7;h/mL (29.4), and 1760 ng&#xb7;h/mL (29.8), respectively (see Table 11).</p><p id="p-0091" num="0084">Following administration of AZD4635 solid oral capsule formulation (Formulation 8a capsule) to human subjects in the fasted state, plasma AZD4635 concentrations were quantifiable from between 0.25 hour and 0.5 hour post-dose. Thereafter, concentrations remained quantifiable until the last sampling occasion at 48 hours post-dose. Maximum plasma concentrations occurred between 1 hour and 2 hours post-dose (median t<sub>max </sub>of 1.5 hours). Geometric mean (CV %) values for C<sub>max</sub>, AUC<sub>0-t </sub>and AUC were 352 ng/mL (31.0), 1850 ng&#xb7;h/mL (28.3) and 1940 ng&#xb7;h/mL (29.0), respectively (see Table 11).</p><p id="p-0092" num="0085">The relative bioavailability of AZD4635 based on C<sub>max </sub>and AUC<sub>0-48 </sub>were 128% and 110%, respectively. Statistical comparisons of geometric mean ratios (GMRs) for C<sub>max </sub>and AUC<sub>0-48 </sub>were 126.71% (90% confidence interval [CI]: 111.12% to 144.48%) and 110.21% (104.33% to 116.42%), respectively, indicating the peak and overall exposure levels for the solid oral capsule formulation (Formulation 8a) were on average 27% and 10% higher than the nano-suspension (Formulation 1). The absorption rate was higher for the solid formulation and resulted in higher peak concentrations.</p><p id="p-0093" num="0000"><tables id="TABLE-US-00015" num="00015"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 11</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of Human Relative Bioavailability Study</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="63pt" align="left"/><colspec colname="3" colwidth="63pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry>Nanosuspension</entry><entry>Capsule</entry></row><row><entry/><entry/><entry>(Formulation 1)</entry><entry>(Formulation 8a)</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>t<sub>max</sub><sup>a </sup>(h)</entry><entry>&#x2009;1.00 (0.50-2.00)</entry><entry>&#x2009;1.50 (1.00-2.00)</entry></row><row><entry/><entry>C<sub>max </sub>(ng/mL)</entry><entry>&#x2002;276 (16.7)</entry><entry>&#x2002;352 (31.0)</entry></row><row><entry/><entry>AUC<sub>0-t </sub>(ng &#xb7; h/mL)</entry><entry>1670 (29.4)</entry><entry>1850 (28.3)</entry></row><row><entry/><entry>AUC<sub>0-48 </sub>(ng &#xb7; h/mL)</entry><entry>1690 (28.4)</entry><entry>1860 (27.7)</entry></row><row><entry/><entry>AUC (ng &#xb7; h/mL)</entry><entry>1760 (29.8)</entry><entry>1940 (29.0)</entry></row><row><entry/><entry>t<sub>1/2&#x3bb;Z </sub>(h)</entry><entry>&#x2009;11.3 (24.9)</entry><entry>&#x2009;11.4 (20.7)</entry></row><row><entry/><entry>F<sub>rel </sub>C<sub>max </sub>(%)</entry><entry>&#x2014;</entry><entry>&#x2002;128 (33.6)</entry></row><row><entry/><entry>F<sub>rel </sub>AUC<sub>0-t </sub>(%)</entry><entry>&#x2014;</entry><entry>&#x2002;110 (12.5)</entry></row><row><entry/><entry>F<sub>rel </sub>AUC<sub>0-48 </sub>(%)</entry><entry>&#x2014;</entry><entry>&#x2002;111 (12.9)</entry></row><row><entry/><entry>F<sub>rel </sub>AUC (%)</entry><entry>&#x2014;</entry><entry>&#x2002;110 (12.9)</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry namest="offset" nameend="3" align="left" id="FOO-00003"><sup>a </sup>Median(range)</entry></row><row><entry/><entry namest="offset" nameend="3" align="left" id="FOO-00004">t<sub>max </sub>= time of maximum observed concentration sampled during a dosing interval</entry></row><row><entry/><entry namest="offset" nameend="3" align="left" id="FOO-00005">C<sub>max </sub>= maximum concentration occurring at t<sub>max</sub></entry></row><row><entry/><entry namest="offset" nameend="3" align="left" id="FOO-00006">AUC<sub>0-t </sub>= area under the drug concentration-time curve from zero to last time point</entry></row><row><entry/><entry namest="offset" nameend="3" align="left" id="FOO-00007">AUC<sub>0-48 </sub>= area under the drug concentration-time curve from zero time to 48 hours</entry></row><row><entry/><entry namest="offset" nameend="3" align="left" id="FOO-00008">AUC = area under the drug concentration-time curve</entry></row><row><entry/><entry namest="offset" nameend="3" align="left" id="FOO-00009">t<sub>1/2&#x3bb;z </sub>= half-life associated with the z component of a polyexponential equation</entry></row><row><entry/><entry namest="offset" nameend="3" align="left" id="FOO-00010">F<sub>rel </sub>= relative bioavailability</entry></row></tbody></tgroup></table></tables></p><p id="p-0094" num="0086">Other embodiments are within the scope of the following claims.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-chemistry idref="CHEM-US-00001" cdx-file="US20230000775A1-20230105-C00001.CDX" mol-file="US20230000775A1-20230105-C00001.MOL"/><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A solid pharmaceutical formulation comprising a plurality of microcrystalline cellulose pellets each individually coated with a composition comprising:<claim-text>6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;</claim-text><claim-text>a polymeric stabilizer;</claim-text><claim-text>an ionic surfactant; and</claim-text><claim-text>a non-ionic surfactant.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The formulation of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein:<claim-text>the polymeric stabilizer includes polyvinylpyrollidone;</claim-text><claim-text>the ionic surfactant includes sodium docusate; and</claim-text><claim-text>the non-ionic surfactant includes a poloxamer or a PEGylated phospholipid.</claim-text></claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The formulation of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00002">2</claim-ref>, wherein:<claim-text>the polymeric stabilizer is polyvinylpyrollidone K-30;</claim-text><claim-text>the ionic surfactant is sodium docusate; and</claim-text><claim-text>the non-ionic surfactant is poloxamer 407.</claim-text></claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The formulation of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00003">3</claim-ref>, wherein the composition further comprises trehalose.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The formulation of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00004">4</claim-ref>, wherein the composition comprises, on a w/w % basis:<claim-text>from 20 to 75% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;</claim-text><claim-text>from 1 to 20% of polyvinylpyrollidone K-30;</claim-text><claim-text>from 0.01 to 1.00% of sodium docusate; and</claim-text><claim-text>from 20 to 60% of poloxamer 407.</claim-text></claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The formulation of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00005">5</claim-ref>, wherein the formulation includes, on a w/w % basis:<claim-text>from 10 to 50% of microcrystalline cellulose;</claim-text><claim-text>from 20 to 50% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;</claim-text><claim-text>from 0.1 to 10% of polyvinylpyrollidone K-30;</claim-text><claim-text>from 0.01 to 1.00% of sodium docusate; and</claim-text><claim-text>from 10 to 40% of poloxamer 407.</claim-text></claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The formulation of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00006">6</claim-ref>, wherein the formulation further comprises a lubricant.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The formulation of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the lubricant includes sodium stearyl fumarate.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The formulation of any one of <claim-ref idref="CLM-00007">claims 7</claim-ref> to <claim-ref idref="CLM-00008">8</claim-ref>, wherein the formulation includes, on a w/w % basis:<claim-text>from 25 to 40% of microcrystalline cellulose;</claim-text><claim-text>from 25 to 45% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;</claim-text><claim-text>from 3 to 7% of PVP K30;</claim-text><claim-text>from 0.05 to 0.50% of sodium docusate;</claim-text><claim-text>from 15 to 35% of poloxamer 407; and</claim-text><claim-text>from 0.01 to 0.5% of sodium stearyl fumarate.</claim-text></claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The formulation of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00009">9</claim-ref>, wherein the formulation includes, on a w/w % basis:<claim-text>from 30 to 35% of microcrystalline cellulose;</claim-text><claim-text>from 33 to 39% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;</claim-text><claim-text>from 4.2 to 5.2% of PVP K30;</claim-text><claim-text>from 0.2 to 0.3% of sodium docusate;</claim-text><claim-text>from 22 to 28% of poloxamer 407; and</claim-text><claim-text>from 0.15 to 0.25% of sodium stearyl fumarate.</claim-text></claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. A solid pharmaceutical formulation comprising a plurality of microcrystalline cellulose pellets each individually coated with a composition, wherein the composition consists essentially of, on a w/w % basis:<claim-text>54.44% of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;</claim-text><claim-text>7.08% of PVP K30;</claim-text><claim-text>0.38% of sodium docusate; and</claim-text><claim-text>38.1% of poloxamer 407.</claim-text></claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. A solid pharmaceutical formulation comprising 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine wherein an oral dose of 50 mg 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine to a human subject provides an AUC<sub>0-48 </sub>of 1850 ng&#xb7;h/mL&#xb1;30%.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. A solid pharmaceutical formulation comprising 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine wherein an oral dose of 50 mg 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine to a human subject provides a C<sub>max </sub>of 352 ng/mL&#xb1;30%.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. A solid pharmaceutical formulation comprising 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine wherein an oral dose of 50 mg 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine to a human subject provides an AUC<sub>0-48 </sub>of 1850 ng&#xb7;h/mL&#xb1;30% and a C<sub>max </sub>of 352 ng/mL&#xb1;30%.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. A solid unit dosage form of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine comprising the formulation according to any one of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00014">14</claim-ref>, wherein the unit dosage form includes 1 to 200 mg of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine in a gelatin capsule.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. A solid unit dosage form of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine comprising the formulation according to any one of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00015">15</claim-ref>, wherein the unit dosage form includes 50, 75, or 100 mg of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine in a gelatin capsule.</claim-text></claim></claims></us-patent-application>